Combination of agomelatine and bupropion for treatment-resistant depression: results from a chart review study including a matched control group

Brain and Behavior
Kurt-Wolfram SühsKai G Kahl

Abstract

Although a growing selection of antidepressants is available, a significant number of patients do not reach clinical remission, despite multiple trials. Data concerning the efficacy and safety of combination therapies with newer antidepressants are limited. Fifteen inpatients with treatment-resistant depression (TRD), defined as Beck Depression Inventory-2 (BDI-2) scores >14 despite treatment with adequate doses of ≥ 1 antidepressant classes for ≥ 6 weeks, were treated with agomelatine plus bupropion for ≥6 weeks, and compared to 15 patients on antidepressant monotherapy with TRD matched on age, sex, and TRD stage based on retrospective chart review. The primary outcome was change in BDI-2 scores. Secondary outcomes included treatment response (BDI-2 score decrease by ≥ 50%), remission (BDI-2 score <13), routinely measured cardiometabolic parameters and adverse effects. After a mean of 6 ± 1 weeks, BDI-2 scores decreased by 20.3 ± 5.6 points in the combination group compared to 12.5 ± 15.1 points in the monotherapy group (P = 0.073; Cohen's d = 0.7). Altogether, 73.3% in the combination group responded compared to 53.3% on monotherapy (P = 0.27). About 60.0% on combination therapy reached remission compared to 40% on monotherap...Continue Reading

References

Dec 1, 1996·Journal of Personality Assessment·A T BeckW Ranieri
Mar 12, 1998·American Journal of Hematology·M M van der KlauwB H Stricker
Oct 27, 2005·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·S H Kennedy, R Emsley
May 5, 2007·The International Journal of Neuropsychopharmacology·Jean Pierre Olié, Siegfried Kasper
Feb 16, 2010·Expert Opinion on Pharmacotherapy·Noah S PhilipLawrence H Price
Nov 11, 2010·The Journal of Clinical Psychiatry·Alessandro Serretti, Laura Mandelli
Jul 2, 2011·Depression and Anxiety·A John Rush
Mar 1, 2012·Journal of Clinical Psychopharmacology·Fábio Lopes RochaCláudia Hara
Mar 1, 2012·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Olga ChernolozPierre Blier
Dec 24, 2013·The American Journal of Psychiatry·Cosmin Sebastian VoicanGabriel Perlemuter
Feb 4, 2014·Journal of Psychiatric Research·Jonathan W StewartPierre Blier
Mar 22, 2014·BMJ : British Medical Journal·David TaylorOlubanke Olofinjana

❮ Previous
Next ❯

Citations

Jul 24, 2020·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·UNKNOWN HimanshuUNKNOWN Nutan
Mar 5, 2021·Journal of Experimental Pharmacology·Mandeep Kaur, Marsal Sanches

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.